Neptinib - CAS 2085843-51-0

Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.

EGFR

JAK/STAT signaling, Tyrosine Kinase/Adaptors, Angiogenesis

2085843-51-0

C22H23ClFN5O2

443.9

N(C=1C2=C(C=C(OCC)C(NC(/C=C/CN(C)C)=O)=C2)N=CN1)C3=CC(Cl)=C(F)C=C3

-20°C

Ice Packs

Small Compound